Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Corautus Genetics, Inc.
Genetics company reports Q4 net loss of $3,708,000
April 26th, 2005
Corautus Genetics, Inc., (VEGF), a biopharmaceutical company dedicated to the development of gene-transfer therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease, reported its financial results for the fourth quarter and fiscal year ended December 31, 2004. For the fourth quarter of 2004, Corautus incurred a net loss of $3,708,000, or $0.25 per share, as compared to a net loss of $1,836,000, or $0.18 per share, in the same period of 2003. Revenues for the fourth quarter of 2004 and 2003 were each $21,000, all of which result from the amortization of a payment received for the sublicense of certain patents...
Source: Cardiovascular Business Week (2005-04-26)
|
